Cargando…
Dual targeting of IGF-1R and ErbB3 as a potential therapeutic regimen for ovarian cancer
Therapeutically targeting receptor tyrosine kinases has proven to be paramount to overcoming chemotherapy resistance in several cancer indications, improving patient outcomes. Insulin-Like Growth Factor Receptor 1 (IGF-1R) and Epidermal Growth Factor Receptor 3 (ErbB3) have been implicated as two su...
Autores principales: | Camblin, Adam J., Tan, Gege, Curley, Michael D., Yannatos, Isabel, Iadevaia, Sergio, Rimkunas, Victoria, Mino-Kenudson, Mari, Bloom, Troy, Schoeberl, Birgit, Drummond, Daryl C., Lugovskoy, Alexey A., Louis, Chrystal U., Askoxylakis, Vasileios |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6856132/ https://www.ncbi.nlm.nih.gov/pubmed/31728045 http://dx.doi.org/10.1038/s41598-019-53322-y |
Ejemplares similares
-
Transcriptional profiling of ErbB signalling in mammary luminal epithelial cells - interplay of ErbB and IGF1 signalling through IGFBP3 regulation
por: Worthington, Jenny, et al.
Publicado: (2010) -
Modulation of ErbB2 Blockade in ErbB2-Positive Cancers: The Role of ErbB2 Mutations and PHLDA1
por: Li, Guangyuan, et al.
Publicado: (2014) -
Endocrine resistance in breast cancer: new roles for ErbB3 and ErbB4
por: Sutherland, Robert L
Publicado: (2011) -
Mutational Screening in Tyrosine-Kinase Domain of erbB1 And erbB2 Genes
por: ALONSO, Juan Manuel Fernández
Publicado: (2005) -
ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC
por: Alvarado, Diego, et al.
Publicado: (2017)